blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
letrotsoli medac 2.5 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
pantoprazole mylan 40 mg injektiokuiva-aine, liuosta varten
mylan ireland limited mylan ireland limited - pantoprazolum natricum sesquihydricum - injektiokuiva-aine, liuosta varten - 40 mg - pantopratsoli
femar 2.5 mg tabletti, kalvopäällysteinen
novartis finland oy - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrolan 2.5 mg tabletti, kalvopäällysteinen
avansor pharma oy - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozole sanoswiss 2.5 mg tabletti, kalvopäällysteinen
sanoswiss uab sanoswiss uab - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozol accord 2.5 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozole bluefish 2.5 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab - letrozolum - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozole sandoz 2.5 mg tabletti, kalvopäällysteinen
sandoz a/s - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli
letrozol stada 2.5 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - letrozole - tabletti, kalvopäällysteinen - 2.5 mg - letrotsoli